Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Nuevas estrategias terapéuticas en la osteoporosis
Información de la revista
Vol. 54. Núm. 8.
Páginas 420-431 (Octubre 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 54. Núm. 8.
Páginas 420-431 (Octubre 2007)
Revision
Acceso a texto completo
Nuevas estrategias terapéuticas en la osteoporosis
New strategies in the treatment of osteoporosis
Visitas
...
Federico Hawkins Carranza??
Autor para correspondencia
fhawkins.hdoc@salud.madrid.org

Correspondencia: Dr. F. Hawkins. Servicio de Endocrinología y Nutrición. Hospital Universitario 12 de Octubre. Avda. de Córdoba, s/n. 28041 Madrid. España.
, Guillermo Martínez Díaz Guerra
Servicio de Endocrinología y Nutrición. Hospital Universitario 12 de Octubre. Madrid. España
Información del artículo

La osteoporosis posmenopáusica es una enfermedad importante por sus repercusiones clínicas en morbilidad y mortalidad, que va en aumento con la mayor longevidad y las modificaciones negativas del estilo de vida de la población. Se revisa tanto su impacto clínico como el epidemiológico en la actualidad, señalando el papel de los factores de riesgo para el diagnóstico de esta afección, cuya definición entraña no sólo la pérdida de densidad mineral ósea, sino también alteraciones en la calidad del hueso. En los últimos años, el arsenal terapéutico para la osteoporosis se ha modificado sustancialmente con fármacos estudiados en ensayos clínicos aleatorizados, a doble ciego y controlados con placebo. Ello permite estudiar su efecto en las fracturas, que constituyen el dato más importante para su utilización. Teniendo en cuenta, por lo tanto, estos nuevos datos y los riesgos porcentuales de fracturas al cabo de 10 años en la población, se puede establecer los criterios terapéuticos que se analiza en esta revisión.

Palabras clave:
Densitometría ósea
Osteoporosis posmenopáusica
Antirresortivos
Anabólicos
Remodelado óseo

Postmenopausal osteoporosis carries substantial morbidity and mortality. The impact of this disease is currently increasing due to greater longevity and negative lifestyle modifications. We review the clinical and epidemiologic impact of postmenopausal osteoporosis, with special emphasis on the risk factors to be considered in the diagnosis of this disease, which involves not only low bone mineral density, but also alterations in bone quality.

In the last few years, the therapeutic arsenal available for the treatment of this disease has changed substantially with drugs that have been tested in randomized, double-blind, placebo-controlled clinical trials. These studies have allowed the effect of these drugs on fractures –the most important data for their use– to be studied. Therefore, taking into account these new reports, as well as the percentage 10-year risk of fracture among the population, therapeutic criteria can be established. These criteria are analyzed in the present review.

Key words:
Bone densitometry
Postmenopausal osteoporosis
Antiresorptive agents
Anabolic therapy
Bone remodeling
El Texto completo está disponible en PDF
Bibliografía
[1.]
WHO Technical Report Series 843.
Assessment of fracture risk and its application to screening for postmenopausal osteoporo sis.
WHO, (1994),
[2.]
C.W. Miller.
Survival and ambulation following hip fracture.
J Bone Joint Surg Am, 60 (1978), pp. 930-934
[3.]
M. Sosa.
La fractura osteoporótica de cadera en España.
Rev Esp Enf Metab, 2 (1993), pp. 189-192
[4.]
O’Johnell, J.A. Kanis.
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.
Osteopor Int, 17 (2006), pp. 1726-1733
[5.]
F. Hawkins, F. Escobar.
Estrategia terapéutica de la osteoporosis.
Alteraciones del metabolismo mineral en Endocrinología, pp. 271-279
[6.]
A.M. Grant, A. Avenell, M.K. Campbell, A.M. McDonald, G.S. MacLennan, G.C. McPherson, et al.
Oral vitamin D3 and cal-cium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial.
Lancet, 365 (2005), pp. 1621-1628
[7.]
M.K. Thomas, D.M. Lloyd-Jones, R.I. Tgadgabu.
Hipovitaminosis D in medical inpatients.
N Engl J Med, 338 (1998), pp. 777-781
[8.]
J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanich, et al.
Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial.
JAMA, 288 (2002), pp. 321-333
[9.]
G.L. Anderson, M. Limacher, A.R. Assaf, et al.
Women’s health initiative steering committee. Effects of conjugated equine es trogen in postmenopausal women with hysterectomy: The women’s Health Initiative randomized controlled trial.
JAMA, 291 (2004), pp. 1701-1712
[10.]
American Society for Bone and Mineral Research Position Statement (regarding the results of the Women’s Health Initiative HRT Trial). Presented by Clifford Rosen, ASBMR 23, 2002. Disponible en: http://www.asbmr.org/news/WHI.cfm
[11.]
A. Cranney, G. Guyatt, N. Krolicki, V. Welch, L. Griffith, J.D. Adachi, et al.
A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis.
Osteopor Int, 12 (2001), pp. 140-151
[12.]
A. Cranney, G. Wells, A. Willan, L. Griffith, N. Zytaruk, V. Robinson, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group, et al.
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
Endocr Rev, 23 (2002), pp. 508-516
[13.]
R.D. Wasnich, Y.Z. Bagger, D.J. Hosking, M.R. McClung, M. Wu, A.M. Mantz, Early postmenopausal intervention cohort study group, et al.
Changes in bone density and turnover after alendronate or estrogen withdrawal.
Menopause, 11 (2004), pp. 622-630
[14.]
H.G. Bone, D. Hoskng, J.P. Devogelaer, J.R. Tucci, R.D. Emkey, R.P. Tonino, et al.
Alendronate Phase III Osteoporosis Treat ment Study Group Ten Years experience with alendronante for osteoporosis in postmenopausal women.
N Engl J Med, 350 (2004), pp. 1189-1199
[15.]
M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Bensen, C. Roux, et al.
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
N Engl J Med, 344 (2001), pp. 333-340
[16.]
D.D. Mellstrom, O.H. Sorensen, S. Goemaere, C. Roux, R.D. Johnson, A.A. Chines.
Seven years of treatment with risedronate in women with postmenopausal osteoporosis.
Calcif Tissue Int, 75 (2004), pp. 462-468
[17.]
C.H. Chesnut, A. Skag, C. Christiansen, R. Recker, J.A. Stakkestad, A. Hosieth, et al.
Oral ibandonate osteoporosis vertebral fracture trial in north America and Europe (BONE).
J Bone Miner Res, 19 (2004), pp. 1241-1249
[18.]
J.Y. Reginster, S. Adami, P. Lakatos, M. Greenwald, J.J.J. Stepan, S.I. Silverman, et al.
Efficafy and tolerability of once monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
Ann Rhem Dis, 65 (2006), pp. 654-661
[19.]
P.D. Delmas, S. Adami, C. Strugals, J.A. Stakkestad, J.Y. Regisnter, D. Felsenberg, et al.
Intravenous ibandronate injections in post menopausal women with osteoporosis: one year results from the doses intravenous administration study.
Arthritis Rheum, 54 (2006), pp. 1838-1846
[20.]
D.M. Black, S. Boonen, J. Cauley, P. Delmas, R. Eastell, I. Reid, et al.
Effect of once yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial.
J Bone Min Res, 21 (2006), pp. S16
[21.]
S.B. Woo, J.W. Hellstein, J.R. Kalmar.
Systematic review: bisphosphonates and osteonecrosis of the jaws.
Ann Intern Med, 144 (2006), pp. 753-761
[22.]
M.J. Favus.
Diabetes and the risk of osteonecrosis of the jaw [editorial].
J Clin Endocrinol Metab, 92 (2007), pp. 817-818
[23.]
C.H. Chesnut, S. Silverman, K. Andriano, H. Genant, A. Gimona, S. Harris, et al.
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
Am J Med, 109 (2000), pp. 267-276
[24.]
E. Barrett-Connor, J.A. Cauley, P.M. Kulkarni, A. Sashegyi, D.A. Cox, M.J. Geiger.
Risk benefit profile for raloxifen: 4 year data from the multiple outcomes of raloxifene evaluation (MORE) randomized trial.
J Bone Miner Res, 19 (2004), pp. 1270-1275
[25.]
E.S. Siris, S.T. Harris, R. Eastell, J.R. Sanchetta, S. Gomeaere, A. Diez Perez, et al.
Continuing outcomes relevant to evista (CORE) investigators. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevan to EVISTA (CORE) study.
J Bone Miner Res, 20 (2005), pp. 1514-1524
[26.]
J. Reeve, P.J. Meunier, J.A. Parsons, M. Bernat, O.L. Bijvoet, P. Courpron, et al.
Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis:a multicentre trial.
Br Med J, 280 (1980), pp. 1340-1344
[27.]
S.P. Shrader, K.R. Ragucci.
Parathyroid hormone (1-84) and treatment of osteoporosis.
Ann Pharmacother, 39 (2005), pp. 1511-1516
[28.]
P. Divieti, N. Inomata, R. Singh, H. Juppner, F.R. Bringhurst.
Receptors for the carboxyl-terminal region of PTH (1-84) are highly expressed in osteocytic cells.
Endocrinology, 142 (2001), pp. 916-925
[29.]
R.M. Locklin, S. Khosla, R.T. Turner, B.L. Riggs.
Mediators of biphasic response of bone to intermittent and continuously administered parathyroid hormone.
J Cell Biochem, 89 (2003), pp. 180-190
[30.]
P.L. Chen, J. Satterwhite, A. Licata, M. Lewiecki, D. Sipos A Misurski, et al.
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmeno pausal women with osteoporosis.
J Bone Miner Res, 20 (2005), pp. 962-970
[31.]
R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, et al.
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med, 344 (2001), pp. 1434-1441
[32.]
R. Lindsay, J. Nieves, C. Formica, E. Henneman, L. Woelfert, V. Shen, et al.
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis.
Lancet, 350 (1997), pp. 550-555
[33.]
J.J. Body, G.A. Gaich, W.H. Scheele, P.M. Kulkarni, P.D. Miller, A. Peretz, et al.
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
J Clin Endocrinol Metab, 87 (2002), pp. 4528-4535
[34.]
M.R. McClung, J. San Martin, P.D. Miller, R. Civitelli, F. Bandeira, M. Omizo, et al.
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
Arch Intern Med, 165 (2005), pp. 1762-1768
[35.]
A.B. Hodsman, D.A. Hanley, M.P. Ettinger, M.A. Bolognese, J. Fox, A.J. Metcalfe, et al.
Safety and efficacy of human parathyroid hormone (1-84) in increasing bone mineral density in postme nopausal osteoporosis.
J Clin Endocrinol Metab, 88 (2003), pp. 5212-5220
[36.]
S.L. Greenspan, H.G. Bone, M.P. Ettinger, D.A. Hanely, R. Lindsay, J.R. Zanchetta, et al.
Effect o recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis.
Ann Intern Med, 146 (2007), pp. 326-339
[37.]
D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, et al.
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteo porosis.
N Engl J Med, 349 (2003), pp. 1207-1215
[38.]
R. Marcus, O. Wang, J. Sattershite, B. Mitlak.
The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
J Bone Miner Res, 18 (2003), pp. 18-23
[39.]
E.S. Orwoll, W.H. Scheele, S. Paul, S. Adami, U. Syversen, A. Diez-Perez, et al.
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
J Bone Miner Res, 18 (2003), pp. 9-17
[40.]
J.L. Vahle, M. Sato, G.G. Long, J.K. Young, P.C. Francis, Engelhardt, et al.
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for two years and relevance to human safety.
Toxicol Pathol, 30 (2002), pp. 312-321
[41.]
C.E. Wilker, J. Jolette, S.Y. Smith, N. Doyle, J.F. Hardisty, A.J. Metcalf, et al.
A no observable carcinogenic effect dose-level identified in Fisher 344 rats following daily treatment with PTH (1-84) for 2 years: role of the C-terminal PTH receptor.
J Bone Miner Res, 19 (2004), pp. S1-S98
[42.]
A.B. Hodsman, D.C. Bauer, D.W. Dempster, L. Dian, D.A. Hanley, S.T. Harris, et al.
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
Endocr Rev, 26 (2006), pp. 688-703
[43.]
R. Lindsay, W.H. Scheele, R. Neer, G. Pohl, S. Adami, C. Mautalen, et al.
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Arch Intern Med, 164 (2006), pp. 2024-2030
[44.]
D.M. Black, J.P. Bilezikian, K.E. Ensrud, S.L. Greenspan, L. Palermo, T. Hue, et al.
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
N Engl J Med, 353 (2005), pp. 555-565
[45.]
N.E. Lane, S. Sánchez, G.W. Modin, H.K. Genant, E. Pierini, C.D. Arnaud.
Bone mass continue to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
J Bone Miner Res, 15 (2000), pp. 944-951
[46.]
E.S. Orwoll, W.H. Scheele, S. Paul, S. Adami, U. Syversen, A. Diez-Perez, et al.
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
J Bone Miner Res, 18 (2003), pp. 9-17
[47.]
W.S. Snyder, M.J. Cook, E.S. Nasset, L.R. Karhausen, G.P. Howells, I.H. Tipton.
Report of the task group on reference. A report prepared by a task group of committee 2 of the international commission on radiological protection.
Pergamon, (1975),
[48.]
S. Pors Nielsen.
The biological role of strontium.
Review. Bone, 35 (2004), pp. 583-588
[49.]
G. El-Hajj Fuleihan.
Strontium ranelate – A novel therapy for osteoporosis or a permutation of the same [editorial].
N Engl J Med, 350 (2004), pp. 504-506
[50.]
P.J. Marie.
Strontium ranelated: a dual mode of action rebalancing bone turnover in favour of bone formation.
Curr Opin Rheumatol, 18 (2006), pp. S1-S15
[51.]
E.M. Brown.
Is the calcium receptor a molecular target for the actions of strontium on bone?.
Osteopor Int, 14 (2003), pp. S25-S34
[52.]
O. Fromigue, A. Barbara, E. Hay, C. Petrel, E. Traiffort, M. Ruat, et al.
Strontiun ranelate stimulates murine osteoblast replication independently of calcium sensing receptor mediated ERK1/2 activation.
Calcif Tissue Int, 78 (2006), pp. S145-S146
[53.]
S. Choudhary, C. Alander, L. Raisz, C. Pibeam.
Strontium ranelate effects on osteoblats: a potential role of endogenous prostaglandins.
J Bone Miner Res, 20 (2005), pp. M424
[54.]
E. Canalis, M. Hott, P. Deloffre, et al.
The divalente strontium salt S12911 enhances bone cell replication and bone formation in vitro.
Bone, 18 (1996), pp. 517-523
[55.]
P.J. Marie, M. Hott, D. Modrowski, C. De Pollak, J. Guilleman, P. Deloffre, et al.
An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen deficient rats.
J Bone Miner Res, 8 (1993), pp. 607-615
[56.]
S. Bain, V. Shen, H. Zheng, I. Dupin-Roger.
Strontium ranelate treatment prevents ovariectomy induced bone loss in rats by maintaining the bone formation at a high level.
Calcif Tissue Int, 74 (2004), pp. 189-194
[57.]
J.Y. Reginter, R. Deroisy, M. Dougados, I. Jupsin, J. Coletter, C. Roux.
Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two year, double masked, dose ranging placebo controlled PREVOS Trial.
Osteopor Int, 13 (2002), pp. 924-931
[58.]
P.J. Meunier, D.O. Slosman, P.D. Delmas, J.L. Sebert, M.L. Brandi, C. Albanese, et al.
Strontium ranelate: dose dependent effects in established postmenopausal vertebral osteoporosis. A 2 year randomized placebo controlled trial.
J Clin Endocrinol Metab, 87 (2002), pp. 2060-2066
[59.]
P.J. Meunier, C. Roux, Seeman, S. Ortolani, J.E. Bauski, T.D. Spector, et al.
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
N Engl J Med, 35 (2004), pp. 459-468
[60.]
J.Y. Regintser, E. Seeman, M.C. De Vernejoul, S. Adami, J. Comston, C. Phenekos, et al.
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporsis: TROPOS Study.
J Clin Endocrinol Metab, 90 (2005), pp. 16-22
[61.]
E. Seeman, B. Vellas, C.L. Benhamou, J.P. Aquin, J. Semler, J.M. Kaufman, et al.
Strontiun raneleate reduces the risk of vertebral and non vertebral fractures in women age and older.
J Bone Miner Res, 7 (2006), pp. 113-120
[62.]
S. Boonen.
Addressing meeting the needs of osteoporotic patients with strontium ranelate: a review.
Curr Opin Rheumatol, 18 (2006), pp. S21-S27
[63.]
M.R. McClung, E.M. Lewiecki, S.B. Cohen, M.A. Bolognese, G.C. Woodson, A.H. Moffet, et al.
Denosumab in postmenopausal women with low bone mineral density.
N Engl J Med, 354 (2006), pp. 821-831
[64.]
D. Marshal, O. Johnell, H. Wedel.
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.
BMJ, 312 (1996), pp. 1254-1259
[65.]
J.A. Kanis, D. Black, C. Cooper, B. Dawson Hughes, C. De Late, et al.
A new approach to the development of assessment guidelines for osteoporosis.
Osteopor Int, 13 (2003), pp. 527-536
[66.]
S.R. Cummings, M.C. Neviitt, W.S. Browner, K. Stone, K.M. Fox, K.E. Ensrud, et al.
Risk factors for hip fracture in white women.
N Engl J Med, 332 (1995), pp. 767-773
[67.]
C.E.D.H. De Late, B.A. Van Tour, H. Burger, A. Hofman, A.E.A.M. Weel, I.H.A.P. Pols.
Hip fracture prediction in elderly men and women: validation in the Rotterdam Study.
J Bone Miner Res, 13 (1998), pp. 1587-1593
[68.]
National Osteoporosis Foundation.
Analysis of the effectiveness and cost of screening and treatment strategies for osteoporosis: a basis for development of practice guidelines.
Osteopor Int, 8 (1998), pp. 1-88
[69.]
P. Ravn, D. Hosking, D. Thompson, G. Cizza, R.D. Wasnich, M. Mc Clung, et al.
Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical makers in the early postmenopausal intervention cohort study.
J Clin Endocrinol Metab, 84 (1999), pp. 2363-2368
[70.]
J.A. Kanis, O. Johnell, A. Oden, I. Sernbo, O. Redlung-Johnel.
Long term risk of osteoporotic fracture in Malmo.
Osteopor Int, 11 (2000), pp. 669-674
[71.]
P.D. Delmas, R. Rizzoli, C. Cooper, J.Y. Reginster.
Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the IOF.
Osteopor Int, 16 (2005), pp. 1-5
[72.]
J.A. Kanis, F. Borgstrom, N. Zethraeus, O. Johnell, A. Oden, B. Jonson.
Intervention thresholds for osteoporosis in the UK.
Bone, (2005), pp. 22-32
[73.]
E.M. Lewiecki.
Nonresponders to osteoporosis therapy.
J Clin Densitom, 6 (2003), pp. 307-314
[74.]
Dietary References Intakes. Washington: Food and Nutrition Board, Institute of Medicine, National Academy Press; 1997.
[75.]
J.A. Kanis, O. Johnell, A. Oden, I. Senbo, I. Redlund-Johnelll, A. Dawson, et al.
Long term risk of osteoporotic fracture in Malmo.
Osteopor Int, 11 (2000), pp. 669-674
[76.]
P.D. Delmas.
Treatment of postmenopausal osteoporosis.
Lancet, 359 (2002), pp. 2018-2026
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos